Rhythm Pharmaceuticals Inc (RYTM) financials
Rhythm Pharmaceuticals revenue and earnings by year
Rhythm Pharmaceuticals's revenue was $190 million in the fiscal year to December 31, 2025, up 45.8% from the year before. Net income was -$197 million, -103.6% of revenue. Since the fiscal year to December 31, 2021, revenue has grown 178.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 190 | 130 | 77 | 24 | 3 |
| Revenue growth | 45.8% | 68.1% | 227.6% | 649.5% | — |
| Gross profit | 170 | 117 | 68 | 22 | 3 |
| Gross margin | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% |
| Operating income | -192 | -266 | -184 | -179 | -170 |
| Operating margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% |
| Net income | -197 | -261 | -185 | -181 | -70 |
| Net margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% |
| Diluted EPS | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 |
| Free cash flow | -117 | -114 | -136 | -174 | -246 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RYTM in Markets.
See also: RYTM returns
No forecast, no recommendation. This page describes Rhythm Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.